learn Follistatin
glycoprotein that inhibits TGF-β and promotes hair growth by antagonizing activin
Search
forLearn
4 / 4 resultslearn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
learn Overview
learn Estradiol
an estrogen promoting hair regrowth more commonly used in women
Research
5 / 1000+ results
research Hair Regrowth Following a Wnt- and Follistatin-Containing Treatment: Safety and Efficacy in a First-in-Man Phase 1 Clinical Trial
The treatment improved hair growth in people with male pattern baldness.
research Faculty Opinions Recommendation of Hair Regrowth Following a Wnt- and Follistatin-Containing Treatment: Safety and Efficacy in a First-in-Man Phase 1 Clinical Trial
New treatment with Wnt proteins and growth factors safely increases hair thickness.
research Regenerative Hair Waves in Aging Mice and Extra-Follicular Modulators Follistatin, Dkk1, and Sfrp4
Aging mice have slower hair regeneration due to changes in signal balance, but the environment, not stem cell loss, controls this, suggesting treatments could focus on environmental factors.
research Targeting the Wnt Pathways for Therapies
Blocking the Wnt pathway could lead to new treatments for cancer and tissue repair but requires careful development to avoid side effects.
research Androgenetic Alopecia: Combing the Hair Follicle Signaling Pathways for New Therapeutic Targets and More Effective Treatment Options
New treatments for hair loss may target specific pathways and generate new hair follicles.
Community Join
5 / 59 resultscommunity Hair Regrowth Following a Wnt- and Follistatin- Containing Treatment: Safety and Efficacy in a First-in-Man Phase 1 Clinical Trial: Scientific, Peer-Reviewed Dermatology Article Indexed with MEDLINE/PubMed
A treatment containing Wnt and Follistatin was found to be safe and effective for hair regrowth in a Phase 1 clinical trial. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community Phase II Clinical Trial for TDM-105795 started recruiting
A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.
community Hair loss causes are still a myth.
The conversation discusses the complexity of hair loss causes, suggesting that DHT sensitivity alone doesn't fully explain it. Treatments mentioned include finasteride and dutasteride.
community Anyone used Topical Calcipotriol (cream) or VPA ( Valproic Acid)
The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.